Medical System Network Co., Ltd. AI Stock Analysis
Want to see JP:4350 full AI Analyst Report?
Medical System Network Co., Ltd. (4350) AI Stock Analysis
Medical System Network Co., Ltd.
(TSE/TYO:4350)
The overall score is very low, driven primarily by a severe deterioration in cash flows, which turned deeply negative. This critical financial weakness is compounded by declining profit margins and bearish technical signals, with the stock trading below key moving averages. A moderate valuation and modest dividend yield provide little support against these significant risks.
Medical System Network Co., Ltd. (4350) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 14.44B
- Dividend Yield
- 2.40%
- Average Volume (3M)
- 99.08K
- Price to Earnings (P/E)
- 21.4
- Beta (1Y)
- 0.29
- Revenue Growth
- 6.89%
- EPS Growth
- -55.21%
- Country
- Japan
- Employees
- 4,014
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Pharmaceuticals
Medical System Network Co., Ltd. Business Overview & Revenue Model
Company Description
Headquartered in Sapporo, Japan, and established in 1999, Medical System Network Co., Ltd. functions as a comprehensive provider within the healthcare industry. Its core business involves the distribution of pharmaceutical products to a diverse range...
Medical System Network Co., Ltd. Financial Statement Overview
Summary
Financial performance is weak. While revenue growth is positive, profitability is deteriorating with declining margins. Most critically, operating and free cash flow turned sharply negative in the latest year, indicating severe liquidity strain. The deleveraged balance sheet is a positive, but it is overshadowed by the cash flow crisis.
Income Statement
40NegativeBalance Sheet
55NeutralCash Flow
20Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 134.23B | 132.19B | 122.39B | 115.36B | 109.55B | 106.69B |
| Gross Profit | 54.03B | 52.77B | 49.60B | 47.93B | 45.92B | 44.43B |
| EBITDA | 6.28B | 6.73B | 6.42B | 6.90B | 6.25B | 7.05B |
| Net Income | 870.00M | 1.07B | 1.26B | 1.86B | 1.61B | 2.39B |
Balance Sheet | ||||||
| Total Assets | 79.29B | 80.10B | 70.63B | 68.19B | 66.27B | 62.98B |
| Cash, Cash Equivalents and Short-Term Investments | 7.28B | 7.74B | 8.46B | 8.27B | 8.14B | 8.20B |
| Total Debt | 30.51B | 37.67B | 29.79B | 29.18B | 30.52B | 29.57B |
| Total Liabilities | 62.16B | 62.68B | 54.28B | 52.97B | 51.78B | 49.69B |
| Stockholders Equity | 17.00B | 17.29B | 16.26B | 15.17B | 14.45B | 13.27B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -5.93B | 1.75B | 5.62B | 3.37B | 1.88B |
| Operating Cash Flow | 0 | -3.44B | 4.46B | 7.72B | 4.97B | 4.01B |
| Investing Cash Flow | 0 | -4.04B | -3.73B | -3.65B | -2.11B | -2.51B |
| Financing Cash Flow | 0 | 6.79B | -544.00M | -3.94B | -2.92B | -3.42B |
Medical System Network Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4350, the sentiment is Negative. The current price of 501.00 is below the 20-day moving average (MA) of 528.55, below the 50-day MA of 515.07, and above the 200-day MA of 500.99, indicating a neutral trend. The MACD of -0.87 indicates Positive momentum. The RSI at 40.52 is Neutral, neither overbought nor oversold. The STOCH value of 5.23 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4350.
Medical System Network Co., Ltd. Peers Comparison
Overall Rating
JP:998982Outperform
JP:339181Outperform
JP:764969Neutral
JP:354967Neutral
JP:334959.9Neutral
JP:435043Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 82Outperform | JPY 485.47B | 15.44 | 11.04% | 3.18% | 3.99% | -0.48% | |
| 81Outperform | JPY 1.11T | 19.85 | 7.13% | 1.90% | ― | ― | |
| 69Neutral | JPY 547.39B | 17.59 | 9.94% | 1.24% | 8.97% | -29.54% | |
| 67Neutral | JPY 473.20B | 24.86 | ― | 1.62% | 12.54% | 15.87% | |
| 60Neutral | JPY 520.98B | 15.87 | ― | 1.29% | 8.99% | 3.61% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 43Neutral | JPY 15.33B | 21.44 | ― | 2.40% | 6.89% | -55.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4350 | Medical System Network Co., Ltd. | 501.00 | 11.20 | 2.29% | |
| JP:9989 | Sundrug Co | 4152.00 | -6.76 | -0.16% | |
| JP:7649 | Sugi Holdings Co | 1408.50 | -394.14 | -21.86% | |
| JP:3391 | TSURUHA Holdings | 2469.50 | -299.95 | -10.83% | |
| JP:3349 | COSMOS Pharmaceutical Corporation | 6371.00 | -969.33 | -13.21% | |
| JP:3549 | KUSURI NO AOKI HOLDINGS CO.,LTD. | 4949.00 | 1081.68 | 27.97% |
Medical System Network Co., Ltd. Corporate Events
Medical System Network Reports 4.7% First-Quarter Sales Growth
Medical System Network Co., Ltd. has businesses in the medical field, including community pharmacy, medical support and medical supply, as well as leasing and facilities, meal catering and home-visit nursing. In the first quarter of the fiscal year e...
Medical System Network Reports Six-Month Sales Growth, Profit Declines
Medical System Network Co., Ltd. reported consolidated sales of ¥66,887 million for the six months ended September 30, 2026, up 4.7% year over year. EBITDA fell 21.0% to ¥2,365 million, while operating profit declined 44.7% to ¥710 million, ordinary...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 18, 2026
